Andoni Gómez-Moreno

Dr. Andoni Gómez-Moreno

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
CWChristina Whitten-Bauer
Christina Whitten-Bauer
JCJosan Chung
Josan Chung
Andoni Gómez-MorenoAndoni Gómez-Moreno
Andoni Gómez-Moreno
PGPilar Gomollón-Zueco
Pilar Gomollón-Zueco
MHMichael D. Huber
Michael D. Huber
UGUrtzi Garaigorta
Urtzi Garaigorta
Development of hepatitis C virus (HCV) infection cell culture systems has permitted the identification of cellular factors that regulate the HCV life cycle. Some of these cellular factors affect steps in the viral life cycle that are tightly associated with intracellular membranes derived from the endoplasmic reticulum (ER). Here, we describe the discovery of erlin-1 protein as a cellular factor that regulates HCV infection. Erlin-1 is a cholesterol-binding protein located in detergent-resistant membranes within the ER. It is implicated in cholesterol homeostasis and the ER-associated degradation pathway. Silencing of erlin-1 protein expression by siRNA led to decreased infection efficiency characterized by reduction in intracellular RNA accumulation, HCV protein expression and virus production. Mechanistic studies revealed that erlin-1 protein is required early in the infection, downstream of cell entry and primary translation, specifically to initiate RNA replication, and later in the infection to support infectious virus production. This study identifies erlin-1 protein as an important cellular factor regulating HCV infection.

23 May 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
Andoni Gómez-MorenoAndoni Gómez-Moreno
Andoni Gómez-Moreno
JGJinchao Guo
Jinchao Guo
HTHeidi M. Temple
Heidi M. Temple
Alexander PlossAlexander Ploss
Alexander Ploss

13 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Andoni Gómez-MorenoAndoni Gómez-Moreno
Andoni Gómez-Moreno
ESEnara San Sebastian
Enara San Sebastian
JMJennifer Moya
Jennifer Moya
PGPilar Gomollón-Zueco
Pilar Gomollón-Zueco
SISergio Isola
Sergio Isola
UGUrtzi Garaigorta
Urtzi Garaigorta
Gene therapy is a promising strategy to treat and cure most inherited metabolic liver disorders. Viral vectors such as those based on adeno-associated viruses (AAVs) and lentiviruses (LVs) are used as vehicles to deliver functional genes to affected hepatocytes. Adverse events associated with the use of high vector doses have motivated the use of small molecules as adjuvants to reduce the dose. In this study, we showed that a one-hour treatment with topoisomerase inhibitors (camptothecin and etoposide) prior to viral transduction is enough to increase AAV and LV reporter expression in non-dividing hepatic cells in culture. Topoisomerase inhibitors increased both integration-competent (ICLV) and integration-deficient (IDLV) LV-derived expression, with a much stronger increase in the IDLV transduction system. In agreement with that, topoisomerase inhibitors increased viral genome integration in both strains, with a greater impact on the IDLV strain, supporting the idea that topoisomerase inhibitors increased episomal DNA integration, especially when viral integrase activity is abolished. These effects correlated with an increase in the DNA damage response produced by the treatments. Our study highlights the need to monitor DNA damage and undesired integration of viral episomal DNAs into the host genome when studying chemical compounds that increase viral transduction.